This is an old revision of this page, as edited by LandAndTree (talk | contribs) at 06:39, 17 January 2025 (Created by translating the page "SK바이오사이언스"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:39, 17 January 2025 by LandAndTree (talk | contribs) (Created by translating the page "SK바이오사이언스")(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)SK Bioscience is a South Korean biotechnology company that produces Vaccines and other products and is a subsidiary of SK Chemicals .
History
SK Chemicals was responsible for all research and development (R&D), production, and sales of chemically synthesized pharmaceuticals, biopharmaceuticals, natural medicines, blood products, and vaccines, but the blood products division was spun off into SK Plasma and the vaccine division into SK Bioscience in July 2018.
In 2024, it acquired the German global pharmaceutical and biotechnology company Cloquet Group and IDT Biologica, a Contract manufacturing organization (CMO) specialized in pharmaceuticals.
SK Bioscience and SK Biopharm are both part of the SK Group, but their governance structures are different: SK Biopharm is part of the SK Inc., while SK Bioscience is part of the SK Discovery Group.
Business
The headquarters is located in Bundang District, Seongnam in Gyeonggi-do. The first cell culture vaccine factory in South Korea is SK Bioscience's Andong vaccine factory. This factory was completed in December 2012 with a total investment of 200 billion won, including 160 billion won in facility investment and 40 billion won in research and development.
References
- "국산 신약 1호 '선플라'…SK, 새 역사를 쓰다[약전약후]". news1. 19 May 2024.
- "SK바이오사이언스, 독일 백신 생산기업 3390억원에 인수". Korea Economic Daily. 27 June 2024.
- "'인수·합병' 마친 바이오 기업들…"실적으로 입증 하겠다"". Newsis. 7 October 2024.
- "SK바이오팜·SK바이오사이언스, 세계 최대 바이오 전시회서 '따로 또 같이' 사업 확장 모색". DongA Ilbo. 4 June 2024.
- "국내 첫 '세포배양' 백신 만드는 SK케미칼 안동공장". news1. 27 November 2013.
